NCT02883556View on ClinicalTrials.gov

Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin

PHASE2CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

March 27, 2017

Primary Completion Date

March 23, 2019

Study Completion Date

December 15, 2020

Conditions
Carcinoma, Squamous Cell
Interventions
DRUG

Pembrolizumab

200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.

Trial Locations (1)

93000

Hôpital Avicenne, Bobigny

All Listed Sponsors
lead

Assistance Publique - Hôpitaux de Paris

OTHER

NCT02883556 - Study of Pembrolizumab as First Line Therapy in Patients With Unresectable Squamous Cell Carcinoma of the Skin | Biotech Hunter | Biotech Hunter